Enhertu Sales in China Surge by 159.5% in Q1 FY2024, Driven by Dual Breast Cancer Indications
Daiichi-Sankyo
Pharmaceutical R&D Developer
On July 31, Daiichi Sankyo Company Limited announced its first quarter of the fiscal year 2024 (April-June) Financial Report.Overall, Daiichi Sankyo's global total revenue was approximately US$2.798 billion (At an exchange rate of 1 USD = 155.89 JPY,436.2 billion yen), an increase of 24.3% year-on-year. The total revenue in mainland China reached 1$10 million（15.7 billion yen), an increase of 0.8% year-on-year.
Screenshot source: Daiichi Sankyo Financial Report
As an ADC star company, ADC is undoubtedly the core layout of Daiichi Sankyo and the pillar of its oncology field.
From April to June, the blockbuster ADC product Trastuzumab Deruxtecan (Enhertu) The global total sales reached$8.31 billion（12.96 billion yen), a year-on-year increase of 58.6%. Daiichi Sankyo expects that in the fiscal year 2024, the product's sales will break through the 3 billion US dollar mark, reachingUSD 3.261 billion.
In the Chinese market, Trastuzumab Deruxtecan (Enhertu) has been approved for 2 breast cancer indications: HER2-positive breast cancer and HER2-low breast cancer, thereby driving sales growth.Revenue in the China region reached 0.15 billion USD (2.4 billion yen), an increase of 159.5% year-on-year.
Screenshot source: Daiichi Sankyo Financial Report
In addition to Trastuzumab Deruxtecan (Enhertu) In addition to this, the ADC drugs in Daiichi Sankyo's pipeline also have many highlights, among which Databotumab (Dato-DXd) has entered the application stage for market approval globally, including in China, and is expected to be approved for marketing in China in the third quarter of 2025.
At the same time, Depatuxizumab (HER3-DXd) In addition to applying for listing in the United States last December, it is also in Phase III clinical trials in China. In May this year, Daiichi Sankyo initiated Depatuxizumab and Rilvegostomig (AZD2936) Combination Therapy for Non-Squamous NSCLC in Phase III Clinical Trial (TROPION-Lung10), as well as the Phase III clinical trial of osimertinib in combination therapy for EGFR-mutated NSCLC (TROPION-Lung14). With the release of the research results, this product is expected to increase Daiichi Sankyo's market share in the oncology field in the future.
In terms of R&D investment, Daiichi Sankyo's R&D expenses in the first quarter of 2024 reached approximately US$646 million (10.0689 Billion Yen), a year-on-year increase of 30.5%. This indicates that the company is increasing its R&D investment in ADC products, especially 5DXd ADCs (Including DS-8201、DS-1062、U3-1402、DS-7300、DS-6000) investment.
ADC Breast Cancer R&D Landscape
Screenshot source: Daiichi Sankyo Financial Report
ADC Lung Cancer R&D Landscape 
Screenshot from: Daiichi Sankyo Financial Report
From the Q1 2024 financial report, Daiichi Sankyo has shown strong performance globally, particularly in the ADC product sector.Trastuzumab Deruxtecan (Enhertu）The significant sales growth demonstrates its competitiveness in the global market. The company has subsequently increased its R&D investment in ADC products, and hopes to further increase its market share through the launch of new products in the future.
Scan the WeChat QR code to add the editor of the Antibody Circle.Those who meet the requirements can join the Antibody Circle WeChat group!
Please indicate: Name + Research Direction!
